A STAT need for human immunologic studies to understand inflammatory bowel disease

American Journal of Gastroenterology

Volumn 100, Issue 1, 2005, Pages 73-74

  Plevy, Scott ^a  

^a UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD2 ANTIGEN; CD28 ANTIGEN; CD4 ANTIGEN; GAMMA INTERFERON; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 10; INTERLEUKIN 12; INTERLEUKIN 6; MITOGEN ACTIVATED PROTEIN KINASE P38; STAT PROTEIN; STAT1 PROTEIN; STAT3 PROTEIN; TRANSACTIVATOR PROTEIN;

CLINICAL RESEARCH; DISEASE MARKER; ENTERITIS; ENZYME ACTIVATION; HUMAN; HUMAN VERSUS ANIMAL COMPARISON; IMMUNOLOGY; INTESTINE MUCOSA; METHODOLOGY; MOLECULAR BIOLOGY; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVIEW; TH1 CELL; ANIMAL; DISEASE MODEL; MOUSE; NOTE; PHYSIOLOGY; SIGNAL TRANSDUCTION;

ANIMALS; DISEASE MODELS, ANIMAL; HUMANS; INFLAMMATORY BOWEL DISEASES; MICE; SIGNAL TRANSDUCTION; TRANS-ACTIVATORS;

EID: 13744257432     PISSN: 00029270     EISSN: 15720241     Source Type: Journal    
DOI: 10.1111/j.1572-0241.2005.41382.x     Document Type: Review

References (13)

1. Hommes D, van den Blink B, Plasse T, et al. Inhibition of stress-activated MAP kinases induces clinical improvement in moderate to severe Crohn's disease. Gastroenterology 2002;122:7.
2. Waetzig GH, Seegert D, Rosenstiel P, et al. p38 mitogen-activated protein kinase is activated and linked to TNF-alpha signaling in inflammatory bowel disease. J Immunol 2002;168:5342.
3. Neurath MF, Becker C, Barbulescu K. Role of NF-kappaB in immune and inflammatory responses in the gut. Gut 1998;43:856.
4. Darnell JE Jr. STATs and gene regulation. Science 1997;277:1630.
5. Papachristou GI, Plevy S. Novel biologies in inflammatory bowel disease. Gastroenterol Clin North Am 2004;33:251.
6. Matsuoka K, Inoue N, Sato T, et al. T-bet upregulation and subsequent interleukin 12 stimulation are essential for induction of Th1 mediated immunopathology in Crohn's disease. Gut 2004;53:1303.
7. Schmidt C, Marth T, Wittig BM, et al. Interleukin-12 antagonists as new therapeutic agents in inflammatory bowel disease. Pathobiology 2002;70:177.
8. Ramana CV, Gil MP, Schreiber RD, et al. Stat1-dependent and -independent pathways in IFN-gamma-dependent signaling. Trends Immunol 2002;23:96.
9. Atreya R, Mudter J, Finotto S, et al. Blockade of interleukin 6 trans signaling suppresses T-cell resistance against apoptosis in chronic intestinal inflammation: Evidence in Crohn's disease and experimental colitis in vivo. Nat Med 2000;6:583.
10. Welte T, Zhang SS, Wang T, et al. STAT3 deletion during hematopoiesis causes Crohn's disease-like pathogenesis and lethality: A critical role of STAT3 in innate immunity. Proc Natl Acad Sci U S A 2003;100:1879.
11. Ito H, Takazoe M, Fukuda Y, et al. A pilot randomized trial of a human anti-interleukin-6 receptor monoclonal antibody in active Crohn's disease. Gastroenterology 2004;126:989.
12. Targan SR, Deem RL, Liu M, et al. Definition of a lamina propria T cell responsive state. Enhanced cytokine responsiveness of T cells stimulated through the CD2 pathway. J Immunol 1995;154:664.
13. Lodes MJ, Cong Y, Elson CO, et al. Bacterial flagellin is a dominant antigen in Crohn's disease. J Clin Invest 2004;113:1296.